2019 Investor Day presentation

ROVI updates its strategy in a meeting with shareholders, investors and analysts.


No votes yet
 
Related
ROVI announces the commencement of the assessment process to obtain marketing authorisation for Doria® in the European Union
ROVI filed its application for marketing authorisation for Doria® with the European health authorities, the European Medicines Agency (EMA...
2 min
31/01/2020
Operating revenue increased by 24% to 270.8 million euros in the first nine months of 2019, mainly driven by the strength of the...
5 min
07/11/2019